ARTICLE
Volume 10,Issue 4
2 April 2025
Epidemiological Analysis of 9,064 Cases of Non-Hodgkin Lymphoma
Li Liu ,
Zhen Ruan
Show Less
1
Quzhou City Qujiang District Life Oasis Public Welfare Service Center, Quzhou 324007, China,
2
Beijing Health Alliance Charitable Foundation, Beijing 100024, China,
PAR 2025 , 9(2), 77–82;
https://doi.org/10.26689/par.v9i2.9964
© 2025 by the Authors. Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Abstract
Objective: This study aimed to investigate the epidemiological characteristics and treatment regimens of non-Hodgkin lymphoma (NHL) in China through a retrospective analysis of 9,064 NHL cases. Methods: Clinical data of 9,064 patients were collected from 555 hospitals in 28 provinces of China. Results: Among 9,064 NHL patients, there were 5,241 males (57.8%) and 3,823 females (42.2%), with a male-to-female ratio of 1.37:1. Patients aged ≥ 45 years old accounted for 89.6%, with a mean age of 61.87 ± 13.30 years. The predominant NHL subtypes were diffuse large B-cell lymphoma (DLBCL, 45.2%), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL, 19.8%), marginal zone lymphoma (MZL, 13.9%), mantle cell lymphoma (MCL, 9.7%), and central nervous system lymphoma (CNSL, 4.3%). Combination therapy served as the primary treatment modality across all NHL subtypes. Conclusions: NHL in China demonstrates male predominance and primarily affects middle-aged and elderly populations, with combination chemotherapy remaining the mainstay therapeutic approach.
References
Laurence D, Jaffe E, 2020, Lymphoma Classification. Cancer Journal (Sudbury, Mass), 26(3): 176–185.
Thandra K, Barsouk A, Saginala K, et al., 2021, Epidemiology of Non-Hodgkin’s Lymphoma. Medical sciences (Basel, Switzerland), 9(1): 5.
Singh R, Shaik S, Negi BS, et al., 2020, Non-Hodgkin’s Lymphoma: A Review. Journal of Family Medicine and Primary Care, 9(4): 1834–1840.
Pratap S, Scordino T, 2019, Molecular and Cellular Genetics of Non-Hodgkin Lymphoma: Diagnostic and Prognostic Implications. Experimental and Molecular Pathology, 106: 44–51.
Huang L, Huang Q, Yang L, 2024, Global and Chinese Epidemiological Characteristics and Prevention of Colorectal Cancer: Interpretation of the 2022 Global Cancer Statistics Report. Chinese Journal of General Surgery and Clinical Medicine, 31(5): 530–537.
Aoki R, Karube K, Sugita Y, et al., 2008, Distribution of Malignant Lymphoma in Japan: Analysis of 2260 Cases, 2001–2006. Pathology International, 58(3): 174–182.
Yang Q, Zhang W, Yu J, et al., 2011, Subtype Distribution of Lymphomas in Southwest China: Analysis of 6,382 Cases Using WHO Classification in a Single Institution. Diagnostic Pathology, 6: 77.
Wang J, Wang Y, Chen Z, et al., 2006, Prevalence of Lymphoma Subtypes in Shanxi According to Latest WHO Classification. Zhonghua Bing Li Xue Za Zhi, Chinese Journal of Pathology, 35(4): 218–223.
Li X, Li G, Gao Z, et al., 2012, Subtype Distribution of Lymphomas in China: A Multicenter Analysis of 10,002 Cases. Journal of Diagnostic Concepts and Practice, 11(2): 111–115.
Roschewski M, Patel M, Reagan P, et al., 2023, Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 29(17): 3301–3312.
Siegel RL, Miller KD, Jemal A, 2018, Cancer Statistics. CA: A Cancer Journal for Clinicians, 68(1): 7–30.
Brown JR, Eichhorst B, Hillmen P, et al., 2023, Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. The New England Journal of Medicine, 388(4): 319–332.
Hou J, Blanc S, Maglinte G, et al., 2024, Real-world Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Patterns and Outcomes Among Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) in US Community Oncology Practices. J Clin Oncol, 42(16): 1.
Kahl B, Dreyling M, Gordon L, et al., 2019, Recent Advances and Future Directions in Mantle Cell Lymphoma Research: Report of the 2018 Mantle Cell Lymphoma Consortium Workshop. Leukemia & Lymphoma, 60(8): 1853–65.
Jain P, Dreyling M, Seymour J, et al., 2020, High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 38(36): 4302–4316.
Jain P, Wang M, 2022, Mantle Cell Lymphoma in 2022-A Comprehensive Update on Molecular Pathogenesis, Risk Stratification, Clinical Approach, and Current and Novel Treatments. American Journal of Hematology, 97(5): 638–656.
Lymphocyte Disease Group, Chinese Society of Hematology, Chinese Medical Association; Lymphoma Expert Committee, Chinese Society of Clinical Oncology (CSCO), 2024, Expert Consensus on Diagnosis and Treatment of Primary Central Nervous System Lymphoma. Leukemia & Lymphoma, (3): 129–137.
Lin ZJ, Xu B, 2024, Advances in the Treatment of Follicular Lymphoma. Leukemia & Lymphoma, (3): 138–141.
Hematologic Oncology Committee, Chinese Anti-Cancer Association; Leukemia and Lymphoma Group, Chinese Society of Hematology; China Anti-Lymphoma Alliance, 2016, Chinese Expert Consensus on the Diagnosis and Treatment of Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia. Chinese Journal of Hematology, 37(9): 729–734.
Share
Back to top
Bio-Byword Scientific Publishing Pty. Ltd.
We are committed to supporting the scientific community by publishing impactful research and fostering effective communication among scientists. We continuously seek ways to accelerate scientific progress while upholding transparency and open dialogue. Our goal is to make knowledge freely and barrier‑free accessible to all.
Contact us: info@bbwpublisher.com
Level 10, 50 Clarence Street Sydney, NSW 2000 Australia